Phase 2 studies typically aren’t statistically significant due to the small n. But leronlimab achieved statistical significance (with room to spare) on a key endpoint, and trended toward SS with at least 2 others. After factoring in the huge drop in SAE’s & AE’s, excellent compassionate results, a pristine safety & tolerability profile based on over 900 patients, and no need for IV administration, I conclude that leronlimab is the most promising COVID drug on the planet.